In translational studies, C5 inhibitor pexelizumab was capable of reducing mortality in patients undergoing coronary artery bypass surgery (112) but not myocardial infarction (113) . Recently, serum levels of C3a and C5a were found to be significantly elevated in patients suffering from stent restenosis after im-plantation of drug-eluting stents in patients with coronary heart disease (114) .